Bavarian Nordic’s new Kvistgård manufacturing plant, the world’s only dedicated industrial-scale MVA vaccine production facility, began test-production in September. The facility’s manufacturing capacity is 40 million doses of IMVAMUNE® per year which, without significant investment, can be increased to 60 million doses.
During the first-half of 2005, Bavarian Nordic industrialised the MVA-BN® production process. In June 2005, the production process was successfully transferred from IDT to the Kvistgård site and testing of the full-scale MVA-BN® manufacturing process began. Activities to validate the plant and production process ran in parallel with the start of operations throughout the remainder of the year and continues in 2006.
In September 2006, the company received manufacturing authorisation from the Danish Medicines Agency to produce MVA-BN® in accordance with full EU cGMP requirements.
Download our supplementary report on the MVA-BN® production process (extract from Annual Report 2005):
